Stock Analiz

NovoCure Ltd (NVCR) stock forecast and price target

Price $11.83 · data as of November 13, 2026

12-month price target

Average target$26.14
Upside / downside+121.0%
Analysts7
ConsensusBuy
Low $15.00Average $26.14High $52.00

Gold marker: average target · white marker: today’s price ($11.83)

Analyst ratings

Strong buy 1Buy 3Hold 3Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-1.05+13.7%$740M
Next fiscal year
ends December 31, 2027
$-0.73+30.9%$809M
Next quarter
ends December 31, 2026
$-0.21+2.7%$190M
Quarter after
ends March 31, 2027
$-0.20+68.5%$189M

Consensus of the analysts covering NovoCure, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.

Our model vs. Wall Street

Analysts see 121.0% upside over 12 months. Our discounted cash flow model with moderate assumptions puts NovoCure’s intrinsic value about 81% below today’s market value, and it scores 0.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the NovoCure stock price target?

The average 12-month target from 7 analysts is $26.14, 121.0% above the current price of $11.83 Targets range from $15.00 to $52.00.

Is NovoCure a buy according to analysts?

The consensus rating is “Buy” (1 strong buy, 3 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is NovoCure expected to earn?

Analysts expect EPS of $-1.05 for the fiscal year ending December 31, 2026 and $-0.73 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.